Clinical trial
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
NCT02247349 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 14, 2014
- Completion date
- December 22, 2022
- Enrollment
- 106 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer